The National Multiple Sclerosis Disease Management Consensus Statement [21] recommends initiating interferon beta or glatiramer DMD therapy as soon as possible following definite diagnosis of active, relapsing MS, and also to consider DMD therapy for selected high risk patients with a first attack. This evidence concerns the gene DMD and multiple sclerosis.